US 11866701
Complement component C3 iRNA compositions and methods of use thereof
granted A61KA61K31/7115
Quick answer
US patent 11866701 (Complement component C3 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/7115